Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus target price of $124.00 for the company and are predicting that the company will post $2.22 EPS for the current quarter, according to Zacks. Zacks has also given Taro Pharmaceutical Industries an industry rank of 187 out of 265 based on the ratings given to related companies.
TARO has been the topic of several analyst reports. ValuEngine upgraded shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. HC Wainwright initiated coverage on shares of Taro Pharmaceutical Industries in a research note on Monday, March 12th. They set a “buy” rating and a $124.00 price target on the stock.
Shares of Taro Pharmaceutical Industries (NYSE TARO) traded down $0.19 during mid-day trading on Monday, reaching $99.37. 28,310 shares of the company traded hands, compared to its average volume of 89,951. Taro Pharmaceutical Industries has a 52 week low of $93.01 and a 52 week high of $128.46. The stock has a market capitalization of $3,992.55, a PE ratio of 19.33 and a beta of 0.64.
Taro Pharmaceutical Industries (NYSE:TARO) last issued its earnings results on Wednesday, February 7th. The company reported $1.37 earnings per share (EPS) for the quarter. Taro Pharmaceutical Industries had a net margin of 30.43% and a return on equity of 11.35%. The company had revenue of $155.46 million for the quarter. equities research analysts expect that Taro Pharmaceutical Industries will post 5.28 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3302651/taro-pharmaceutical-industries-ltd-taro-given-consensus-rating-of-strong-buy-by-analysts.html.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.